Treatment Effects vs Headlines in Retatrutide Comparisons
A headline commonly highlights one arm and one analysis. The study may also include other target amounts, alternate estimands, adverse events and outcomes with different levels of certainty.
A headline commonly highlights one arm and one analysis. The study may also include other target amounts, alternate estimands, adverse events and outcomes with different levels of certainty.
TRIUMPH-1 compared retatrutide with placebo over 80 weeks. In the sponsor’s efficacy analysis, the 12 mg arm showed a 28.3% average reduction in body weight, compared with 2.2% with placebo.
TRIUMPH-1 studied adults with obesity without diabetes. Other parts of the retatrutide program include adults with type 2 diabetes, often under separate trial protocols.
The 28.3% figure is an average reduction for the 12 mg trial arm at 80 weeks under the sponsor-reported efficacy analysis. The corresponding placebo estimate was 2.2%.
A superiority result applies to a defined outcome, comparison, population and time point. SURMOUNT-5 found greater mean weight reduction with tirzepatide than semaglutide over 72 weeks in its tested population.
Lilly reported an extension of TRIUMPH-1 for 532 participants who had a baseline BMI of at least 35 and completed and tolerated treatment in the main study. Follow-up extended to 104 weeks.
Gastrointestinal events were the most common adverse events in the retatrutide Phase 2 obesity trial. The study also reported a dose-related increase in heart rate that peaked during follow-up and then declined.
The Phase 2 obesity study reported outcomes across 1 mg, 4 mg, 8 mg and 12 mg assigned groups. The Phase 3 TRIUMPH-1 paper describes 4 mg, 9 mg and 12 mg research arms.
Gastrointestinal adverse events were prominent in the retatrutide obesity program. Studies generally report the type of event and how frequently it was observed in each group.
The Phase 2 paper reported an estimated mean weight change of −8.7% at 48 weeks in the 1 mg retatrutide group, compared with −2.1% in the shared placebo group.